Can Proteomics Refine Lung Screening?
Proteomic biomarkers improve short-term lung cancer risk assessment.
By
Kathryn Wighton
June 1, 2026
Clinical Scorecard: Can Proteomics Refine Lung Screening?
At a Glance
Category Detail
Condition Lung Cancer Risk Assessment Key Mechanisms Utilizes 13 circulating protein biomarkers to estimate short-term lung cancer risk. Target Population Individuals with a smoking history, particularly those at high risk for lung cancer. Care Setting Clinical settings for lung cancer screening and risk assessment.
Key Highlights
INTEGRAL-Risk model predicts lung cancer within 1 year with an AUC of 0.88. Captures 85% of lung cancer cases within 1 year, outperforming PLCOm2012 and USPSTF 2021 criteria. Model improves discrimination among ineligible screening candidates under USPSTF 2021 criteria. Discriminative advantage diminishes over longer follow-up periods. Recalibration is recommended before clinical implementation. Guideline-Based Recommendations
Diagnosis
Use the INTEGRAL-Risk model as a prescreening tool for lung cancer risk estimation. Management
Refine eligibility for low-dose computed tomography screening based on INTEGRAL-Risk model results. Monitoring & Follow-up
Monitor performance and recalibrate the model as necessary for diverse populations. Risks
Consider limitations such as lack of assessment of lung cancer mortality and false-positive results. Patient & Prescribing Data
Participants with a smoking history from diverse racial and ethnic backgrounds.
Model shows improved sensitivity for detecting incident lung cancer compared to questionnaire-based approaches.
Clinical Best Practices
Incorporate protein biomarker analysis in lung cancer risk assessment. Conduct adequately powered prospective studies for broader implementation. Related Resources & Content
